LONDON – Vicentra BV has bounced back from COVID-19 related disruptions of its supply chain to raise a €10 million (US$11.44 million) round that will enable the company to reshape manufacturing and get its wireless insulin pump back on the market later in the year.
The Xpert MTB/XDR test developed by the Foundation for Innovative New Diagnostics (FIND) and Cepheid Inc. quickly indicates whether a patient has a dangerous – and rapidly increasing – strain of multidrug resistant tuberculosis (TB). The new test enables clinicians to return results in 90 minutes and see immediately whether the pathogen would respond to standard first- or second-line therapies.
PARIS – Affluent Medical SA recently raised $17.8 million in new financing. This will be used to bring forward the clinical program for its minimally invasive implants, designed to restore physiological function in patients suffering from structural heart disease as well as urinary incontinence.
LONDON – An independent U.K. inquiry has found that failure to take seriously concerns raised by patients has resulted in life-threatening problems caused by medical devices and drugs being ignored for decades.
Ongoing litigation between rivals Edwards Lifesciences Corp. and Abbott Laboratories is over, with the two settling all outstanding patent disputes in cases related to transcatheter mitral and tricuspid repair products. Details of the settlement remain confidential.
LONDON – Europe has its fourth new fund in less than a month with the launch of Eir Ventures, which arrives on the scene with €76 million (US$85.9 million) to invest in life science startups in the Nordic countries of Norway, Denmark, Sweden and Finland.
Balt Extrusion SAS has received CE mark approval for its Silk Vista flow diverting stent for those with unruptured intracranial aneurysms. Flow diverters aim to divert blood flow away from an aneurysm, allowing it to heal and reducing the risk of rupture.
A large epidemiological study published in the July 6, 2020, advance online issue of The Lancet found that most individuals who became infected with SARS-CoV-2 developed antibodies to the virus, confirming that infection usually results in at least a short-term immune response.
Mastor SAS secured €3 million (US$3.39 million) in seed investment from Sofinnova Partners' MD Start III Fund and €1.9 million in non-dilutive funding through the i-Nov Innovation Award from BPI France, the French national public investment bank.
PARIS – Quantum Surgical SAS said it has achieved a world first at the Montpellier University Hospitals by successfully using its medical robot to perform surgery on three patients with liver cancer.
RSS
